GSI_6

Carbometrics’ publication on glucose-sensitive insulin in collaboration with Novo Nordisk and the University of Bristol has been featured in Nature magazine

Carbometrics, in collaboration with Novo Nordisk and University of Bristol has published a paper in Nature magazine on the Glucose Sensitive Insulin.

As Selvedge Venture, we are very proud of the work Carbometrics has done and are looking forward to witnessing the many different ways they inspire innovation in diabetes care and contribute to improved patient outcomes. 

Their groundbreaking research not only paves the way for advanced treatment options but also underscores the importance of collaborative efforts in the scientific community. We anticipate exciting developments as they continue to push the boundaries of what’s possible in healthcare.

What is Glucose Sensitive Insulin and how were Ziylo/Carbometrics involved in this project?

AI_collection_hero-7cd68d878c8b910a5114df2f4293f251 (1)

Three Selvedge Venture portfolio companies were featured in the April issue of Nature

Nature has published their April 2022 Biopharma Dealmakers collection on the Advances in Artificial Intelligence-Driven Drug Development presenting companies “harnessing the power of artificial intelligence for the development of cutting-edge tools and novel approaches to accelerate drug discovery and research”. 

We are very excited to have three Selvedge Venture Life Sciences AI companies featured in this collection! Click the links below to view the individual articles:

BIOS Health: Using data-driven insigths from the nrevous system to build neural digital therapies

Exogene Ltd: How artificial intelligence is enabling T cell receptor screening for cell therapy discovery

Multiomic Health Limited: Leveraging deep omics data to tackle a global health challenge with precision